Id: acc0587
Group: 1sens
Protein: DHX9
Gene Symbol: DHX9
Protein Id: Q08211
Protein Name: DHX9_HUMAN
PTM: phosphorylation
Site: Ser321
Site Sequence: IGKLAQFEPSQRQNQVGVVPW
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: HCT116
Disease Info:
Drug: oxaliplatin (OXA)
Drug Info: "Oxaliplatin (OXA) is a third-generation platinum-based chemotherapeutic agent primarily used in the treatment of colorectal, gastric, pancreatic, and other cancers, which inhibits DNA synthesis by inducing cross-linking damage, thereby blocking replication and transcription and triggering apoptosis."
Effect: inhibit
Effect Info: Oxaliplatin makes cells resistant to oxaliplatin through PI3KK-mediated phosphorylation of DHX9.
Note:
Score: 5.0
Pubmed(PMID): 32187976
Sentence Index:
Sentence:

Sequence & Structure:

MGDVKNFLYAWCGKRKMTPSYEIRAVGNKNRQKFMCEVQVEGYNYTGMGNSTNKKDAQSNAARDFVNYLVRINEIKSEEVPAFGVASPPPLTDTPDTTANAEGDLPTTMGGPLPPHLALKAENNSEVGASGYGVPGPTWDRGANLKDYYSRKEEQEVQATLESEEVDLNAGLHGNWTLENAKARLNQYFQKEKIQGEYKYTQVGPDHNRSFIAEMTIYIKQLGRRIFAREHGSNKKLAAQSCALSLVRQLYHLGVVEAYSGLTKKKEGETVEPYKVNLSQDLEHQLQNIIQELNLEILPPPEDPSVPVALNIGKLAQFEPSQRQNQVGVVPWSPPQSNWNPWTSSNIDEGPLAFATPEQISMDLKNELMYQLEQDHDLQAILQERELLPVKKFESEILEAISQNSVVIIRGATGCGKTTQVPQFILDDFIQNDRAAECNIVVTQPRRISAVSVAERVAFERGEEPGKSCGYSVRFESILPRPHASIMFCTVGVLLRKLEAGIRGISHVIVDEIHERDINTDFLLVVLRDVVQAYPEVRIVLMSATIDTSMFCEYFFNCPIIEVYGRTYPVQEYFLEDCIQMTHFVPPPKDKKKKDKDDDGGEDDDANCNLICGDEYGPETRLSMSQLNEKETPFELIEALLKYIETLNVPGAVLVFLPGWNLIYTMQKHLEMNPHFGSHRYQILPLHSQIPREEQRKVFDPVPVGVTKVILSTNIAETSITINDVVYVIDSCKQKVKLFTAHNNMTNYATVWASKTNLEQRKGRAGRVRPGFCFHLCSRARFERLETHMTPEMFRTPLHEIALSIKLLRLGGIGQFLAKAIEPPPLDAVIEAEHTLRELDALDANDELTPLGRILAKLPIEPRFGKMMIMGCIFYVGDAICTIAAATCFPEPFINEGKRLGYIHRNFAGNRFSDHVALLSVFQAWDDARMGGEEAEIRFCEHKRLNMATLRMTWEAKVQLKEILINSGFPEDCLLTQVFTNTGPDNNLDVVISLLAFGVYPNVCYHKEKRKILTTEGRNALIHKSSVNCPFSSQDMKYPSPFFVFGEKIRTRAISAKGMTLVTPLQLLLFASKKVQSDGQIVLVDDWIKLQISHEAAACITGLRAAMEALVVEVTKQPAIISQLDPVNERMLNMIRQISRPSAAGINLMIGSTRYGDGPRPPKMARYDNGSGYRRGGSSYSGGGYGGGYSSGGYGSGGYGGSANSFRAGYGAGVGGGYRGVSRGGFRGNSGGDYRGPSGGYRGSGGFQRGGGRGAYGTGYFGQGRGGGGY

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
DHX9-Ser321
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A431 Afatinib 5.607 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A459 SelumetinibMK2206-3to1 7.2601 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 AZD8055 8.0779 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 Dasatinib 6.2358 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 Dasatinib 2.9807 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 MK2206 9.1673 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 Nintedanib 5.7662 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 PD325901 10.8362 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 Staursporin 4.8537 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR A549 Tideglusib 12.7269 -
Q08211 DHX9 P Ser321 LAQFEPS(ph)QR K562 Imatinib 7.7743 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: